Seagen to Highlight Data from Expanding Oncology Portfolio at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
Seagen Inc. has announced significant data presentations at the 2022 ASCO Annual Meeting, highlighting its cancer treatment advancements. Key presentations include groundbreaking overall survival data for ADCETRIS in Hodgkin lymphoma patients and interim results from the innovaTV 205 trial of TIVDAK for cervical cancer. The company plans to submit supplemental applications to the FDA to update ADCETRIS's prescribing information. These findings emphasize Seagen's commitment to addressing unmet medical needs across multiple cancer types.
- Groundbreaking overall survival data for ADCETRIS in Stage III/IV Hodgkin lymphoma.
- Interim results from the innovaTV 205 trial of TIVDAK in cervical cancer presented.
- Plans to submit FDA applications to expand ADCETRIS's indications to children.
- None.
– Data from 26 abstracts, including four oral presentations, underscore
Other important data include interim results from the dose-expansion cohorts of the innovaTV 205 trial of TIVDAK® (tisotumab vedotin-tftv) in combination with other anticancer agents in patients with recurrent metastatic cervical cancer, which will also be featured in an oral presentation. Long-term outcomes from the phase 3 EV-301 trial of PADCEV® (enfortumab vedotin-ejfv) in patients with previously treated advanced urothelial carcinoma will be shared in a poster discussion.
“Significant improvements in overall and event-free survival are important new findings in adult and pediatric Hodgkin lymphoma patients, respectively,” said
Key data presentations for
Presentations of Company-Sponsored Trials
Abstract Title |
Abstract # |
Presentation |
Lead Author |
ADCETRIS® (brentuximab vedotin) |
|||
First-line brentuximab vedotin plus chemotherapy to improve overall survival in patients with Stage III/IV classical Hodgkin lymphoma: An updated analysis of ECHELON-1 |
7503 |
Oral
|
|
Brentuximab vedotin in combination with lenalidomide and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma: Safety and efficacy results from the safety run-in period of the phase 3 ECHELON-3 study |
7559 |
Poster
|
|
Updated safety and efficacy data from an open-label, phase 1/2 study of frontline brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine (A+AVD) in pediatric patients with advanced-stage classical Hodgkin lymphoma (cHL) |
10000 |
Oral
|
|
The impact of classic Hodgkin lymphoma (cHL) on informal caregivers: Results from the cHL: Real-world observations from physicians, patients, and caregivers on the disease and its treatment (CONNECT) study |
E24004
|
Online Publication |
|
PADCEV® (enfortumab vedotin-ejfv) |
|||
Long-term outcomes in EV-301: 24-month findings from the phase 3 trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma |
4516 |
Poster Discussion
|
|
Study EV-103 Cohort H: Antitumor activity of neoadjuvant treatment with enfortumab vedotin monotherapy in patients with muscle-invasive bladder cancer who are cisplatin-ineligible |
4582 |
Poster
|
|
Benchmarking maintenance therapy survival in first-line advanced urothelial carcinoma using disease modeling |
4575 |
Poster
|
|
Real world treatment patterns and clinical outcomes with first-line therapy in cisplatin-eligible and ineligible patients with advanced urothelial carcinoma |
4565 |
Poster
|
G. P. Sonpavde |
TIVDAK ® (tisotumab vedotin-tftv) |
|||
Factors associated with receipt of second-line recurrent or metastatic cervical cancer treatment in |
5532 |
Poster
|
|
Cervical cancer geographical burden analyzer: An interactive, open-access tool for understanding geographical disease burden in patients with recurrent or metastatic cervical cancer |
5523 |
Poster Discussion
|
|
Tisotumab vedotin (TV) + pembrolizumab (pembro) in first-line (1L) recurrent or metastatic cervical cancer (r/mCC): Interim results of ENGOT Cx8/GOG 3024/innovaTV 205 |
5507 |
Oral
|
|
Productivity losses under various second-line recurrent or metastatic cervical cancer treatment scenarios in |
E17520 |
Online Publication |
|
Patterns of care in Medicaid-enrollees with recurrent or metastatic cervical cancer |
E17525 |
Online Publication |
C. A. Leath |
TIVDAK® (tisotumab vedotin-tftv) Trials in Progress |
|||
Trial in progress update on ENGOT-cx8/GOG-3024/innovaTV 205: Addition of a new cohort with first-line (1L) tisotumab vedotin (TV) + pembrolizumab (pembro) + carboplatin (carbo) ± bevacizumab (bev) in recurrent/metastatic cervical cancer (r/mCC) |
TPS5603 |
Poster
|
I. Vergote |
innovaTV 207: New combination dosing cohorts in the open label phase 2 study of tisotumab vedotin in solid tumors |
TPS6100 |
Poster
|
|
TUKYSA® (tucatinib) Trials in Progress |
|||
Phase 3 study of tucatinib or placebo in combination with trastuzumab and pertuzumab as maintenance therapy for HER2+ metastatic breast cancer (HER2CLIMB-05, trial in progress) |
TPS1108 |
Poster
|
|
Phase 2 trial of tucatinib + trastuzumab deruxtecan in patients with HER2+ locally advanced or metastatic breast cancer with and without brain metastases (HER2CLIMB-04, trial in progress) |
TPS1111 |
Poster
|
|
Disitamab vedotin |
|||
Preliminary results of a phase Ib/II combination study of RC48-ADC, a novel humanized anti-HER2 antibody-drug conjugate (ADC) with toripalimab, a humanized IgG4 mAb against programmed death-1 (PD-1) in patients with locally advanced or metastatic urothelial carcinoma |
4518 |
Poster Discussion
|
|
A phase II study of RC48-ADC in HER2-negative patients with locally advanced or metastatic urothelial carcinoma |
4519 |
Poster Discussion
|
|
RC48-ADC for metastatic urothelial carcinoma with HER2 -positive: Combined analysis of RC48-C005 and RC48-C009 trials
|
4520 |
Poster Discussion
|
|
Pipeline Trials in Progress |
|||
Phase 1 study of SGN-B7H4V, a novel, investigational vedotin antibody–drug conjugate directed to B7-H4, in patients with advanced solid tumors (SGNB7H4V-001, trial in progress) |
TPS3155 |
Poster
|
A. Patnaik |
Phase 1 study of SGN-PDL1V, a novel, investigational vedotin antibody–drug conjugate directed to PD-L1, in patients with advanced solid tumors (SGNPDL1V-001, trial in progress) |
TPS3154 |
Poster
|
A. Patnaik |
Phase 1 study of SGN-ALPV, a novel, investigational vedotin antibody–drug conjugate directed to ALPP/ALPPL2 in advanced solid tumors (SGNALPV-001, trial in progress) |
TPS3159 |
Poster
|
|
Phase 1b/2 study of ladiratuzumab vedotin (LV) in combination with pembrolizumab for first-line treatment of triple-negative breast cancer (SGNLVA-002, trial in progress) |
TPS1127 |
Poster
|
|
Presentations of Investigator-Sponsored or Cooperative Group Trials
Abstract Title |
Abstract # |
Presentation |
Lead Author |
Brentuximab vedotin and association with event-free survival (EFS) in children with newly diagnosed high-risk Hodgkin lymphoma (HL): A report from the |
7504 |
Oral
|
|
Brentuximab vedotin and nivolumab alone and then combined with rituximab, cyclophosphamide, doxorubicin, and prednisone for frontline therapy of patients with primary mediastinal large B-cell lymphoma |
TPS7589 |
Poster
|
|
About
Forward-Looking Statements
Certain statements made in this press release are forward looking, such as those, among others, relating to the company’s pipeline and the therapeutic potential of ADCETRIS, PADCEV, TUKYSA, TIVDAK, disitamab vedotin, ladiratuzumab vedotin and the company’s other product candidates, including their efficacy, safety and potential therapeutic uses. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include without limitation the difficulty and uncertainty of pharmaceutical product development, including the risks that the company may experience delays in its clinical trials or otherwise experience failures or setbacks in its clinical development programs due to lack of efficacy, adverse events or other factors, and that adverse regulatory actions may occur. More information about the risks and uncertainties faced by
View source version on businesswire.com: https://www.businesswire.com/news/home/20220428005429/en/
For Media
Vice President, Corporate Communications
(310) 430-3476
dcaouette@seagen.com
For Investors
Senior Vice President, Investor Relations
(425) 527-4160
ppinkston@seagen.com
Source:
FAQ
What data will Seagen present at the ASCO Annual Meeting 2022?
What is the significance of the data for ADCETRIS presented by Seagen?
When is the ASCO Annual Meeting 2022 taking place?
What are Seagen's plans regarding ADCETRIS after the ASCO presentations?